Skip to main navigation Skip to search Skip to main content

Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice

Edgardo Falcon, Kaitlyn Maier, Shivon A. Robinson, Tiffany E. Hill-Smith, Irwin Lucki*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

Rationale: Buprenorphine (BPN) has been shown to rapidly improve mood in treatment-resistant depressed patients in small clinical studies. However, BPN's effects in preclinical tests for mood and antidepressant efficacy are largely unexplored. Objective: The current study examined the effects of BPN in the forced swim test (FST) and novelty-induced hypophagia (NIH) test as measures of antidepressant and anxiolytic-like effects in C57BL/6 J mice. Microdialysis was used to measure whether BPN engaged kappa-opioid receptor (KORs) in the nucleus accumbens shell (NAcSh) at a behaviorally active dose (0.25 mg/kg). Methods: BPN was tested in the FST at both 30 min and 24 h post-administration. Also measured in the FST at 24 h post-administration were the KOR antagonist norbinaltorphimine (nor-BNI), the MOR agonist morphine and the reference antidepressant desipramine. The anxiolytic effects of BPN were examined in the NIH test 24 h after treatment. The effects of acute injection of BPN and the KOR agonist U50,488 were measured on extracellular dopamine (DA) levels in the NAcSh. Results: BPN produced significant reductions in FST immobility without changing locomotor activity and reduced approach latencies in the novel environment of the NIH test when tested 24 h after treatment. Repeated daily BPN injections for 6 days did not produce tolerance to these behavioral effects. nor-BNI produced a similar antidepressant-like response in the FST 24 h post-injection but morphine and desipramine were ineffective. BPN (0.25 mg/kg) did not alter DA levels when given alone but prevented the KOR agonist U50,488 from reducing DA levels. Conclusions: Acute and subchronic treatment with BPN produced antidepressant and anxiolytic-like responses in mice at doses that engage KORs. These studies support the clinical evidence that BPN may be a novel rapid-acting antidepressant medication and provides rodent models for investigating associated neurochemical mechanisms.

Original languageEnglish
Pages (from-to)907-915
Number of pages9
JournalPsychopharmacology
Volume232
Issue number5
DOIs
StatePublished - Jan 2015

Keywords

  • Antidepressant
  • Anxiety
  • Buprenorphine
  • Depression
  • Dopamine
  • Kappa-opioid receptor
  • Microdialysis

Fingerprint

Dive into the research topics of 'Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice'. Together they form a unique fingerprint.

Cite this